Therapeutic options for low bone mineral density in HIV-infected subjects

Current HIV/AIDS Reports

Volumn 9, Issue 2, 2012, Pages 148-159

  Cotter, Aoife G ^a,b   Mallon, Patrick W G ^a,b  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

Author keywords

Antiretroviral therapies; Bone mineral density; HIVinfection; Management; Osteoporosis

Indexed keywords

ALENDRONIC ACID; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB; EFAVIRENZ; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; VITAMIN D; ZIDOVUDINE; ZOLEDRONIC ACID; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BONE DENSITY CONSERVATION AGENT;

ACUTE PHASE RESPONSE; ALGORITHM; ANDROGEN DEPRIVATION THERAPY; ANTIVIRAL THERAPY; ARTICLE; BODY MASS; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CELL DIFFERENTIATION; CELLULITIS; DIARRHEA; DIZZINESS; DRUG WITHDRAWAL; ECZEMA; ESTROGEN DEFICIENCY; ESTROGEN THERAPY; FALL RISK; FEMUR SUBTROCHANTERIC FRACTURE; FOLLOW UP; FRACTURE; FRACTURE HEALING; FRACTURE REDUCTION; FRAGILITY FRACTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HIP FRACTURE; HOT FLUSH; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCALCEMIA; JAW OSTEONECROSIS; LEG CRAMP; MEDICAL HISTORY; META ANALYSIS (TOPIC); MORTALITY; NAUSEA; NEPHROTOXICITY; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PATHOGENESIS; PATIENT MONITORING; PHASE 2 CLINICAL TRIAL (TOPIC); PREMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANCE TRAINING; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SMOKING; SMOKING CESSATION; TREATMENT DURATION; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; WRIST FRACTURE; DRUG EFFECT;

ANTI-HIV AGENTS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; HIV INFECTIONS; HUMANS; OSTEOPOROSIS;

EID: 84863991280     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-012-0117-9     Document Type: Article

References (112)

1. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993 Jun;94(6):646-50.
2. Bhavan KP, Kampalath VN, Overton ET. The aging of the HIV epidemic. Curr HIV/AIDS Rep. 2008;5(3):150-8.
3. Martin CP, Fain MJ, Klotz SA. The older HIV-positive adult: a critical review of the medical literature. Am J Med. 2008;121 (12):1032-7.
4. Rockville MDoHaHS. Bone health and osteoporosis: a report of the Surgeon General. In: Department of Health and Human Services, editor. 2004.
5. van Staa TP, Dennison EM, Leufkens HG, Cooper C. Epidemiology of fractures in England and Wales. Bone. 2001;29 (6):517-22. (Pubitemid 33124293)
6. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006;20(17):2165-74. (Pubitemid 44684707)
7. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. J Clin Endocrinol Metab. 2008;93(9):3499-504.
8. Young B, Dao CN, Buchacz K, Baker R, Brooks JT Increased rates of bone fracture among HIV-infected persons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000-2006. Clin Infect Dis. 2011;52(8):1061-8.
9. Womack JA, Goulet JL, Gibert C, Brandt C, Chang CC, Gulanski B, et al. Increased risk of fragility fractures among HIV infected compared to uninfected male veterans. PLoS One. 2011;6(2):e17217.
10. Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch Intern Med. 1991;151 (10):2026-32.
11. Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int. 1994;4(6): 368-81.
12. Siris ES, Chen YT, Abbott TA, Barrett-Connor E, Miller PD, Wehren LE, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164(10):1108-12 [Research Support, Non-U.S. Gov't]. (Pubitemid 38668990)
13. Kanis JA, Burlet N, Cooper C, Delmas PD, Reginster JY, Borgstrom F, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2008;19 (4):399-428.
14. Libois A, Clumeck N, Kabeya K, Gerard M, De Wit S, Poll B, et al. Risk factors of osteopenia in HIV-infected women: no role of antiretroviral therapy. Maturitas. 2009;65(1):51-4.
15. Calmy A, Fux CA, Norris R, Vallier N, Delhumeau C, Samaras K, et al. Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study. J Infect Dis. 2009;200(11):1746-54 [Research Support, Non-U.S. Gov't].
16. Duvivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcrip-tase inhibitor regimens in HIV-1 infected naive patients. AIDS. 2009;23(7):817-24 [Comparative Study Randomized Controlled Trial Research Support, Non-U.S. Gov't].
17. Madeddu G, Spanu A, Chessa F, Calia GM, Lovigu C, Mannazzu M, et al. Serum leptin and bone metabolism in HIV patients treated with highly active antiretroviral therapy. Q J Nucl Med Mol Imaging. 2009;53(3):290-301.
18. Tomazic J, Ul K, Volcansek G, Gorensek S, Pfeifer M, Karner P, et al. Prevalence and risk factors for osteopenia/osteoporosis in an HIV-infected male population. Wien Klin Wochenschr. 2007;119 (21-22):639-46. (Pubitemid 350239502)
19. Brown TT, Ruppe MD, Kassner R, Kumar P, Kehoe T, Dobs AS, et al. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia. J Clin Endocrinol Metab. 2004;89(3):1200-6. (Pubitemid 38368413)
20. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36(4):482-90. (Pubitemid 36241317)
21. Moore AL, Vashisht A, Sabin CA, Mocroft A, Madge S, Phillips AN, et al. Reduced bone mineral density in HIV-positive individuals. AIDS. 2001;15(13):1731-3. (Pubitemid 32918130)
22. Fausto A, Bongiovanni M, Cicconi P, Menicagli L, Ligabo EV, Melzi S, et al. Potential predictive factors of osteoporosis in HIV-positive subjects. Bone. 2006;38(6):893-7. (Pubitemid 44500653)
23. Carr A, Miller J, Eisman JA, Cooper DA. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy. AIDS. 2001;15(6):703-9. (Pubitemid 32423217)
24. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Lo Y, Klein RS. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS. 2007;21(5):617-23.
25. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Santoro N, Schoenbaum EE. HIV infection and bone mineral density in middle-aged women. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2006;42 (7):1014-20.
26. Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metab. 2006;91(8):2938-45. (Pubitemid 44271739)
27. Nolan D, Upton R, McKinnon E, John M, James I, Adler B, et al. Stable or increasing bone mineral density in HIV-infected patients treated with nelfinavir or indinavir. AIDS. 2001;15(10):1275-80. (Pubitemid 32592360)
28. Cazanave C, Lawson-Ayayi S, Barthe N, Uwamaliya-Nziyumvira B, Kpozehouen A, Mehsen N, et al. Changes in bone mineral density: 2-year follow-up of the ANRS CO3 aquitaine cohort. CROI. 2010: Abstract 747.
29. Bonjoch A, Figueras M, Estany C, Perez-Alvarez N, Rosales J, del Rio L, et al. High prevalence of and progression to low bone mineral density in HIV-infected patients: a longitudinal cohort study. AIDS. 2010;24(18):2827-33 [Research Support, Non-U.S. Gov't].
30. van Vonderen MG, Lips P, van Agtmael MA, Hassink EA, Brinkman K, Geerlings SE, et al. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS. 2009;23(11):1367-76.
31. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaerden E, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2010;51(8):963-72 [Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't].
32. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a sub-study of ACTG A5202. J Infect Dis. 2011;203(12):1791-801
33. van Voderen MGA, Mallon PW, Murray B, Doran P, van Agtmael MA, Danner SA, et al. Changes in bone biomarkers in antiretro-viral naïve HIV-infected men randomised to nevirapine/lopinavir/ritonavir (NVP/LPV/r) or zidovudine/lamivudine/lopinavir/rito-navir (AZT/3TC/LPV/r) help explain limited loss of bone mineral density over first 12 months. 18th Conference on Retroviruses and Opportunistic Infections. 2011;Feb 27-Mar 2 2011, Boston, MA: Abstract O-296.
34. Brown TT, Ross AC, Storer N, Labbato D, McComsey GA. Bone turnover, osteoprotegerin/RANKL and inflammation with antire-troviral initiation: tenofovir versus non-tenofovir regimens. Anti-vir Ther. 2011;16(7):1063-72 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
35. EACS. EACS Prevention and Management of Non-Infectious Co-Morbidities in HIV 2009.
36. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2010;51(8):937-46 [Research Support, Non-U.S. Gov't Review].
37. Ryan PJ, Blake GM, Herd R, Parker J, Fogelman I. Post-menopausal vertebral osteoporosis: can dual energy X-ray absorptiometry forearm bone density substitute for axial measurements? Br J Rheumatol. 1994;33(6):546-9 [Comparative Study]. (Pubitemid 24179258)
38. Patel R, Blake GM, Panayiotou E, Fogelman I. Clinical evaluation of a phalangeal bone mineral density assessment system. J Clin Densitom. 2010;13(3):292-300 [Evaluation Studies].
39. National Osteoporosis Foundation. America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation. In: Foundation NO, editor. Washington, DC2002.
40. NOG. Guideline for the diagnosis and management of osteoporosis in post-menopausal women and men over the age of 50 years in the U.K. 2010 July 2010.
41. Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C, et al. Exercise for preventing and treating osteoporosis in postmen-opausal women. Cochrane Database Syst Rev. (7): CD000333.
42. Tang BM, Eslick GD, Nowson C, Smith C, Bensoussan A. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis. Lancet. 2007;370(9588):657-66. (Pubitemid 47285316)
43. Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ.341:c3691.
44. Bolland MJ, Grey A, Avenell A, Gamble GD, Reid IR. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ.342:d2040.
45. Bolland MJ, Grey A, Gamble GD, Reid IR. Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women's Health Initiative (WHI) limited-access data set. Am J Clin Nutr. Oct;94(4):1144-9.
46. Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, et al. Global vitamin D status and determinants of hypovitaminosis D. Osteoporos Int. 2009;20(11):1807-20 [Research Support, Non-U.S. Gov't Review].
47. Dao CN, Patel P, Overton ET, Rhame F, Pals SL, Johnson C, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis. Feb 1;52(3):396-405.
48. Adeyemi OM, Agniel D, French AL, Tien PC, Weber K, Glesby MJ, et al. Vitamin D deficiency in HIV-infected and HIV-uninfected women in the United States. J Acquir Immune Defic Syndr. 2011;57(3):197-204 [Research Support, American Recovery and Reinvestment Act Research Support, N.I.H., Extramural].
49. Stephensen CB, Marquis GS, Kruzich LA, Douglas SD, Aldrovandi GM, Wilson CM. Vitamin D status in adolescents and young adults with HIVinfection. Am J Clin Nutr. 2006;83(5):1135-41. (Pubitemid 44713115)
50. Dao CN, Patel P, Overton ET, Rhame F, Pals SL, Johnson C, et al. Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America. 2011;52 (3):396-405 [Research Support, U.S. Gov't, P.H.S.].
51. Brown TT, McComsey GA. Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther. 2010;15(3):425-9 [Research Support, N.I.H., Extramural].
52. Wohl D, Doroana M, Orkin C, et al. Change in vitamin D levels smaller and risk of development of severe vitamin D deficiency lower among HIV-1-infected, treatment-naive adults receiving TMC278 compared with EFV: 48-week results from the phase III ECHO trial. 18th Conference on Retroviruses and Opportunistic Infections. 2011;February 27-March 2, 2011.: Abstract no. 79LB.
53. Allavena C, Delpierre C, Rey D, et al. Effects of ARVon vitamin D concentration in HIV-infected patients: a large prospective cohort analysis. 18th Conference on Retroviruses and Opportunistic Infections. 2011;February 27-March 2, 2011.: Abstract no. 826.
54. Fox J, Peters B, Prakash M, Arribas J, Hill A, Moecklinghoff C. Improvement in vitamin D deficiency following antiretroviral regime change: Results from the MONET trial. AIDS Res Hum Retrovir. 2011;27(1):29-34 [Randomized Controlled Trial].
55. Mueller NJ, Fux CA, Ledergerber B, Elzi L, Schmid P, Dang T, et al. High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS. May 15;24(8):1127-34.
56. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2011 Jun 6.
57. Roelofs AJ, Thompson K, Ebetino FH, Rogers MJ, Coxon FP. Bisphosphonates: molecular mechanisms of action and effects on bone cells, monocytes and macrophages. Curr Pharm Des.16 (27):2950-60.
58. Russell RG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci. 2007;1117:209-57. (Pubitemid 350191297)
59. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomised trial of effect of alendr-onate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348(9041):1535-41. (Pubitemid 26411651)
60. Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85(11):4118-24. (Pubitemid 32055362)
61. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999;282 (14):1344-52. (Pubitemid 29483192)
62. Delmas PD, Recker RR, Chesnut 3rd CH, Skag A, Stakkestad JA, Emkey R, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int. 2004;15 (10):792-8. (Pubitemid 39361949)
63. Chesnut IC, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19(8):1241-9. (Pubitemid 41094364)
64. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, et al. Once-yearly zoledronic acid for treatment of postmenopaus-al osteoporosis. N Engl J Med. 2007;356(18):1809-22. (Pubitemid 46698462)
65. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343(9):604-10. (Pubitemid 30659471)
66. Zhong ZM, Chen JT. Anti-fracture efficacy of risedronic acid in men: a meta-analysis of randomized controlled trials. Clin Drug Investig. 2009;29(5):349-57.
67. Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JD, Pieper CF, Mautalen C, et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med. 2007;357: nihpa40967.
68. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. BMJ.341:c4444.
69. Cardwell CR, Abnet CC, Cantwell MM, Murray LJ. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA. Aug 11;304(6):657-63.
70. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005;353(1):99-102. discussion 99-.
71. Black DM, Schwartz AV, Ensrud KE, Cauley JA, Levis S, Quandt SA, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296 (24):2927-38. (Pubitemid 46021497)
72. Bolland MJ, Grey AB, Horne AM, Briggs SE, Thomas MG, Ellis-Pegler RB, et al. Annual zoledronate increases bone density in highly active antiretroviral therapy-treated human immunodeficiency virus-infected men: a randomized controlled trial. J Clin Endocrinol Metab. 2007;92(4):1283-8. (Pubitemid 46556399)
73. Guaraldi G, Orlando G, Madeddu G, Vescini F, Ventura P, Campostrini S, et al. Alendronate reduces bone resorption in HIV-associated osteopenia/ osteoporosis. HIV Clin Trials. 2004;5 (5):269-77 [Clinical Trial Multicenter Study Randomized Controlled Trial]. (Pubitemid 39545399)
74. Huang JS, Wilkie SJ, Sullivan MP, Grinspoon S. Reduced bone density in androgen-deficient women with acquired immune deficiency syndrome wasting. J Clin Endocrinol Metab. 2001;86 (8):3533-9. (Pubitemid 32755940)
75. McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, et al. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS. 2007;21(18):2473-82. (Pubitemid 350145179)
76. Mondy K, Powderly WG, Claxton SA, Yarasheski KH, Royal M, Stoneman JS, et al. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection. J Acquir Immune Defic Syndr. 2005;38(4):426-31. (Pubitemid 40381552)
77. Negredo E, Martinez-Lopez E, Paredes R, Rosales J, Perez-Alvarez N, Holgado S, et al. Reversal of HIV-1-associated osteoporosis with once-weekly alendronate. AIDS. 2005;19(3):343-5. (Pubitemid 40396568)
78. Rozenberg S, Lanoy E, Bentata M, Viard JP, Valantin MA, Missy P, et al. Effect of alendronate on HIV-associated osteoporosis: a randomized, double-blind, placebo-controlled, 96-week trial (ANRS 120). AIDS research and human retroviruses. 2012 Feb 22.
79. Huang J, Meixner L, Fernandez S, McCutchan JA. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS. 2009;23 (1):51-7 [Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't].
80. Hughes DE, Dai A, Tiffee JC, Li HH, Mundy GR, Boyce BF. Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-beta. Nat Med. 1996;2(10):1132-6.
81. Taranta A, Brama M, Teti A, De luca V, Scandurra R, Spera G, et al. The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone. 2002;30(2):368-76. (Pubitemid 34150159)
82. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-33. (Pubitemid 34761611)
83. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmen-opausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282 (7):637-45. (Pubitemid 29384151)
84. Ensrud KE, Stock JL, Barrett-Connor E, Grady D, Mosca L, Khaw KT, et al. Effects of raloxifene on fracture risk in postmen-opausal women: the Raloxifene Use for the Heart Trial. J Bone Miner Res. 2008;23(1):112-20.
85. Bekker PJ, Holloway D, Nakanishi A, Arrighi M, Leese PT, Dunstan CR. The effect of a single dose of osteoprotegerin in postmenopausal women. J Bone Miner Res. 2001;16(2):348-60. (Pubitemid 32105416)
86. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, et al. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19(7):1059-66. (Pubitemid 41110556)
87. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, et al. Denosumab in postmeno-pausal women with low bone mineral density. N Engl J Med. 2006;354(8):821-31. (Pubitemid 43290920)
88. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007;22(12):1832-41. (Pubitemid 351229299)
89. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222-9.
90. Watts NB, Roux C, Modlin JF, Brown JP, Daniels A, Jackson S, et al. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? Osteoporosis international: a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2012;23(1):327-37 [Research Support, Non-U.S. Gov't].
91. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in post-menopausal women with osteoporosis. N Engl J Med. 2009;361 (8):756-65.
92. Migliaccio S, Brama M, Spera G. The differential effects of bisphosphonates, SERMS (selective estrogen receptor modulators), and parathyroid hormone on bone remodeling in osteoporosis. Clin Interv Aging. 2007;2(1):55-64.
93. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434-41. (Pubitemid 32402100)
94. Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18(1):9-17. (Pubitemid 36008334)
95. Kurland ES, Heller SL, Diamond B, McMahon DJ, Cosman F, Bilezikian JP. The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]. Osteoporos Int. 2004;15 (12):992-7. (Pubitemid 40064654)
96. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer RM. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. N Engl J Med. 2003;349(13):1216-26. (Pubitemid 37152031)
97. Finkelstein JS, Wyland JJ, Lee H, Neer RM. Effects of teripara-tide, alendronate, or both in women with postmenopausal osteoporosis. J Clin Endocrinol Metab. 2010;95(4):1838-45.
98. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al. The effects of parathyroid hormone and alendro-nate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349(13):1207-15. (Pubitemid 37152030)
99. Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol. 2002;30(3):312-21. (Pubitemid 34556102)
100. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350(5):459-68 [Clinical Trial Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]. (Pubitemid 38133766)
101. Cooper C, Reginster JY, Chapurlat R, Christiansen C, Genant H, Bellamy N, et al. Efficacy and safety of oral strontium ranelate for the treatment of knee osteoarthritis: rationale and design of randomised, double-blind, placebo-controlled trial. Curr Med Res Opin. 2012;28(2):231-9.
102. Reginster JY, Seeman E, De Vernejoul MC, Adami S, Compston J, Phenekos C, et al. Strontium ranelate reduces the risk of non-vertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90(5):2816-22 [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't]. (Pubitemid 40686329)
103. Ringe JD, Dorst A, Farahmand P. Efficacy of strontium ranelate on bone mineral density in men with osteoporosis. Arzneimittel-forschung. 2010;60(5):267-72.
104. Curran A, Martinez E, Saumoy M, del Rio L, Crespo M, Larrousse M, et al. Body composition changes after switching from protease inhibitors to raltegravir: SPIRAL-LIP substudy. AIDS. 2012;26 (4):475-81 [Research Support, Non-U.S. Gov't].
105. Bloch M, Tong W, Hoy J, Baker D, Richardson R, Carr A. Improved low BMD and bone turnover markers with switch from Tenofovir to Raltegravir in virologically suppressed HIV-1+ adults at 48 weeks: The TROP Study. CROI. 2012: Abstract 878.
106. Peris P, Guanabens N, Martinez de Osaba MJ, Monegal A, Alvarez L, Pons F, et al. Clinical characteristics and etiologic factors of premenopausal osteoporosis in a group of Spanish women. Semin Arthritis Rheum. 2002;32(1):64-70. (Pubitemid 35001166)
107. Bhalla AK. Management of osteoporosis in a pre-menopausal woman. Best Pract Res Clin Rheumatol. Jun;24(3):313-27.
108. Khosla S. Update in male osteoporosis. J Clin Endocrinol Metab. 2010;95(1):3-10.
109. Smith MR, Fallon MA, Lee H, Finkelstein JS. Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89(8):3841-6. (Pubitemid 39071482)
110. Lewiecki EM, Gordon CM, Baim S, Leonard MB, Bishop NJ, Bianchi ML, et al. International Society for Clinical Densitometry 2007 Adult and Pediatric Official Positions. Bone. 2008;43 (6):1115-21.
111. Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev. 2005;26(4): 97-122.
112. Seibel MJ. Biochemical markers of bone turnover part II: clinical applications in the management of osteoporosis. Clin Biochem Rev. 2006;27(3):123-38.